Prothena Corporation plc - Ordinary Shares (PRTA) News

Prothena Corporation plc - Ordinary Shares (PRTA): $22.29

-0.49 (-2.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

Filter PRTA News Items

PRTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRTA News Highlights

  • For PRTA, its 30 day story count is now at 6.
  • Over the past 25 days, the trend for PRTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PRTA are RARE, AL and MD.

Latest PRTA News From Around the Web

Below are the latest news stories about Prothena Corp Public Ltd Co that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in connection with hiring Dr. Hideki Garren as Prothena’s Chief Medical Officer, the compensation committee of the Company’s board of directors granted Dr. Garren, an option to purchase 250,000 ordinary shares of the Company. Such stock option has an exercise price per share equal to $24.90, which was the closing trading price on April 5, 2021, the date of the grant. In addition, in connection with hiring a new employee, the compensation committee of the Company’s board of directors granted the individ...

Yahoo | April 7, 2021

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Dr. Garren’s extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company’s transition to a fully-integrated R&D and commercial businessDUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the appointment of Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will lead the clinical and medical organizations to advance Prothena’s clinical pipeline. “Hideki brings valuable experience and expertise to our team as we look ahead towards transitioni...

Yahoo | April 5, 2021

What Type Of Shareholders Make Up Prothena Corporation plc's (NASDAQ:PRTA) Share Registry?

If you want to know who really controls Prothena Corporation plc ( NASDAQ:PRTA ), then you'll have to look at the...

Yahoo | March 29, 2021

Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | March 25, 2021

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that it priced an underwritten public offering of 3,500,000 of its ordinary shares at a price to the public of $20.75 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares. Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $67...

Yahoo | March 24, 2021

Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 13, 2021

The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 10) AVEO …

Benzinga | March 11, 2021

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s diseaseNew analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to initiate Phase 2b PADOVA study in 2Q21Investor conference call and webcast scheduled for Thursday, March 11, at 4:30PM ET DUBLIN, Ireland, March 08, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, will hold an investor webcast Thursday, March 11, at 4:30 PM ET to review three oral presentations made at The 15th International Conference o...

Yahoo | March 8, 2021

The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings

Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts. Morphic Holding Inc (NASDAQ: MORF ) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients. M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ: FPRX ) in an $1.9-billion all-cash deal. Here are the key catalysts for the unfolding week: Conferences Chardan's 3rd Annual Microbiome Medicines Summit: March 8 H.C. Wainwright Global Life Sciences Conference: March 9-11 Bar...

Benzinga | March 6, 2021

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

Corvus Pharmaceuticals (NASDAQ: CRVS ) shares are … Full story available on Benzinga.com

Benzinga | February 12, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.381 seconds.